Kyl’s Patent Reform Bill Gains Acceptance From Drug And Biotech Industries
This article was originally published in The Tan Sheet
Executive Summary
Sen. Jon Kyl plans to take up the patent reform legislation battle in the next Congress after the Senate deadlocked on Judiciary Committee Chairman Patrick Leahy's proposal
You may also be interested in...
Democrats’ Gains Galvanize Leahy’s Push For Patent Reform
Encouraged by election results that increased Democrats' majority in the Senate, Judiciary Committee Chairman Patrick Leahy, D-Vt., will reintroduce his controversial patent reform bill
Senators Oppose Patent Reform Provisions; GSK Also Urges Revisions To Bill
As patent reform legislation heads toward the Senate floor, members of the biotech and pharmaceutical industries are imploring legislators to alter key provisions. And a group of Senators is criticizing the bill's formulation for apportioning damage awards in infringement suits
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC